8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Inclisiran (Leqvio) is FDA-approved for LDL-C lowering in ASCVD patients, but its role in reducing cardiovascular events is still being defined. This guide covers trial data from ORION-10, ORION-11, and ORION-4, side effects, cost, and where inclisiran fits in the ASCVD treatment algorithm.
A clinical evidence summary of inclisiran (Leqvio) use in familial hypercholesterolemia, including FDA-approved HeFH data from ORION-9 and off-label HoFH data from ORION-5, with GRADE-level assessments and guideline context.
Inclisiran (Leqvio) is FDA-approved for ASCVD, not familial hypercholesterolemia. Learn the off-label dosing protocol, ORION trial evidence, and how clinicians are using it for HeFH.
Inclisiran (Leqvio) is FDA-approved for heterozygous familial hypercholesterolemia and clinical ASCVD requiring additional LDL lowering. This evidence summary reviews the off-label rationale, trial data, and guideline context for using Leqvio in broader ASCVD secondary prevention.
A clinician-focused review of inclisiran (Leqvio) for ASCVD secondary prevention, covering off-label status, LDL-C efficacy data from ORION trials, dosing protocol, and guideline context.
A clinician-reviewed guide to using inclisiran (Leqvio) off-label for ASCVD secondary prevention, covering the evidence base, FDA-approved indications, GRADE ratings, dosing, and monitoring requirements.
Inclisiran (Leqvio) is FDA-approved for atherosclerotic CVD but used off-label for familial hypercholesterolemia. Learn the evidence base, GRADE rating, dosing, and monitoring protocols.
Can Leqvio (inclisiran) be used for familial hypercholesterolemia? Explore the off-label evidence, FDA-approved indications, clinical trial data, and physician considerations before prescribing inclisiran for FH.